Onconova, a privately held Delaware Corporation, is developing innovative products for combating cancer. We are creating novel Solutions for Oncology by combining conventional pharmaceutical science (a small molecule approach) with the latest genomic and genetic technologies for drug discovery and development.

Anticipated Milestones

Phase II and proof of concept of ON 01910.Na, Onconova’s most advanced anti-cancer agent, in Q4-2008.

ON 013105 for Mantle Cell Lymphoma - IND in Q4-2008.

Human testing is expected in 2008 to support approval of Onconova's radiation protection drug, Ex-RAD™. This program is developed under FDA “Animal Rule” guidance.

read more